menu
    • menu

    Company profile for Longbio Pharma

    NEW Drugs in Dev: 3
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    LongBio Pharma is a biotech company based in Shanghai, China, established in 2018. The company has a focus on autoimmune and rare diseases with a commitment to serving patients and society. Dr. Sun, Bill, Nai-chau, co-founder of LongBio Pharma, has a notable background as the co-founder of Tanox, which went public on Nasdaq in 2000 and was later acquired by Genentech in 2007. He is also the co-inventor of Omalizumab (Xolair®)...
    LongBio Pharma is a biotech company based in Shanghai, China, established in 2018. The company has a focus on autoimmune and rare diseases with a commitment to serving patients and society. Dr. Sun, Bill, Nai-chau, co-founder of LongBio Pharma, has a notable background as the co-founder of Tanox, which went public on Nasdaq in 2000 and was later acquired by Genentech in 2007. He is also the co-inventor of Omalizumab (Xolair®), the first anti-IgE antibody approved by the FDA, with global sales reaching 3.6 billion USD in 2022. LongBio Pharma aims to introduce its drugs to both domestic and international markets through partnerships.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Longbio PharmaChina Flag
    Country
    Country
    China
    Address
    Address
    Dongnan Avenue, Changshu, Jiangsu
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.longbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/longbio/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    LongBio Pharma Lists on Hong Kong Stock Exchange
    LongBio Pharma Lists on Hong Kong Stock Exchange

    05 Jun 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/chinas-leading-innovative-drug-developer-for-allergic-and-autoimmune-diseases-longbio-pharma-lists-on-hong-kong-stock-exchange-302792533.html

    PR NEWSWIRE
    05 Jun 2026
    Share Share
    Longbio Launches IPO on Autoimmune & Allergic Disease Pipeline
    Longbio Launches IPO on Autoimmune & Allergic Disease Pipeline

    29 May 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7489917

    FIRSTWORD PHARMA
    29 May 2026
    Share Share
    Longbio Reveals Positive Phase II CSU Trial Results For LP-003
    Longbio Reveals Positive Phase II CSU Trial Results For LP-003

    02 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/superior-efficacy-and-long-acting-longbio-announces-positive-topline-results-from-phase-ii-csu-trial-of-next-generation-anti-ige-therapy-lp-003-in-head-to-head-comparison-with-xolair-302701088.html

    PR NEWSWIRE
    02 Mar 2026
    Share Share
    Longbio Unveils Ph 2 Data on LP-003 in CSU at AAAAI 2025
    Longbio Unveils Ph 2 Data on LP-003 in CSU at AAAAI 2025

    03 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/breakthrough-exciting-interim-phase-ii-data-of-lp-003-in-csu-released-by-longbio-at-aaaai-2025-302389413.html

    PR NEWSWIRE
    03 Mar 2025
    Share Share
    LongBio's LP-003 achieves its fourth IND approval
    LongBio's LP-003 achieves its fourth IND approval

    25 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/food-allergy-longbios-lp-003-achieves-its-fourth-ind-approval-302315417.html

    PR NEWSWIRE
    25 Nov 2024
    Share Share
    LongBio Completes Series B2 Financing Led by Qiming Venture Partners
    LongBio Completes Series B2 Financing Led by Qiming Venture Partners

    24 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/longbio-announced-the-completion-of-series-b2-financing-led-by-qiming-venture-partners-302256825.html

    PR NEWSWIRE
    24 Sep 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search